{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:11Z","timestamp":1793367131624,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejso.2026.112097","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:59:42Z","timestamp":1787727582000},"page":"112097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is uniform D2 still biologically optimal in gastric cancer? Lymphadenectomy in the immunotherapy era"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-5636","authenticated-orcid":false,"given":"Wojciech P.","family":"Polkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucjan S.","family":"Wyrwicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.ejso.2026.112097_bib1","first-page":"1","article-title":"Japanese GC treatment guidelines 2021","year":"2023","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2026.112097_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"10.1016\/j.ejso.2026.112097_bib3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"ESMO guidelines committee. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","article-title":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial","volume":"11","author":"Songun","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/bjs.1800820321","article-title":"New method to evaluate the therapeutic value of lymph node dissection for GC","volume":"82","author":"Sasako","year":"1995","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.112097_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.111361","article-title":"Efficacy of D2 plus lymph node dissection for GC","volume":"52","author":"Matsumoto","year":"2026","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib7","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1245\/s10434-017-5857-8","article-title":"Incidence and prognostic value of metastases to posterior and para-aortic lymph nodes in resectable GC","volume":"24","author":"Marrelli","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib8","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/cancers16071376","article-title":"Posterior and para-aortic (D2plus) lymphadenectomy after neoadjuvant\/conversion therapy for locally advanced\/oligometastatic GC","volume":"16","author":"Marrelli","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejso.2026.112097_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced GC with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17_suppl","key":"10.1016\/j.ejso.2026.112097_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001","volume":"42","author":"Al-Batran","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112097_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"10184","key":"10.1016\/j.ejso.2026.112097_bib12","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112097_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-01069","article-title":"Targeted molecular profiling of circulating cell-free DNA in patients with gastroesophageal adenocarcinoma","volume":"10","author":"Cytryn","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(25)00027-0","article-title":"Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial","volume":"26","author":"van der Wilk","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/bjs.1800830836","article-title":"Benefits of D2 lymph node dissection for patients with GC and pN0 and pN1 lymph node metastases","volume":"83","author":"Siewert","year":"1996","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.112097_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112097_bib17","first-page":"859","article-title":"Efficacy and safety of pembrolizumab or placebo plus chemotherapy in patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: KEYNOTE-859","volume":"402","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112097_bib18","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared with adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejso.2026.112097_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110454","article-title":"Influence of lymphadenectomy extent on the efficacy of immunotherapy in recurrent GC patients","volume":"51","author":"Zhu","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1 checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejso.2026.112097_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ejso.2026.112097_bib22","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","article-title":"The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes","volume":"185","author":"Huang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejso.2026.112097_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","article-title":"CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor","volume":"56","author":"Prokhnevska","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ejso.2026.112097_bib24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejso.2026.112097_bib25","article-title":"Prime suspect or collective responsibility: impact of specific lymph node station dissection on short- and long-term outcomes among locally advanced GC patients after neoadjuvant chemotherapy","volume":"51","author":"S\u0119d\u0142ak","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.humpath.2021.07.003","article-title":"Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes","volume":"116","author":"Tsekrekos","year":"2021","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.ejso.2026.112097_bib27","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.5858\/arpa.2021-0225-OA","article-title":"Data set for reporting carcinoma of the stomach in gastrectomy: recommendations from the International collaboration on cancer reporting","volume":"146","author":"Shi","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejso.2026.112097_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2026.111928","article-title":"Bridging prediction and reality: AI-based external validation of predictive models for lymph node metastasis in gastric cancer","author":"Santos","year":"2026","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib29","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/SLA.0000000000002444","article-title":"Surgicopathological quality control and protocol adherence to lymphadenectomy in the CRITICS gastric cancer trial","volume":"268","author":"Claassen","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112097_bib30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s12029-019-00321-x","article-title":"How should we measure the quality of lymphadenectomy for gastric cancer? Anatomical versus numerical criterion","volume":"51","author":"Rausei","year":"2020","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ejso.2026.112097_bib31","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-026-19957-8","article-title":"Survival comparison of proximal and total gastrectomy after neoadjuvant therapy in Siewert type II\/III gastric adenocarcinoma: a real-world multicenter cohort study","author":"Wen","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2026.111901","article-title":"Beyond margin length: integrating tumour biology into the extent of gastrectomy","volume":"52","author":"Polkowski","year":"2026","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/jso.70251","article-title":"Pathologic response and outcomes after neoadjuvant chemotherapy in gastric cancer: a NCDB analysis","author":"Hwang","year":"2026","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/bjs.9345","article-title":"Randomized clinical trial comparing survival after D1 or D2 gastrectomy for GC","volume":"101","author":"Degiuli","year":"2014","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.112097_bib35","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/bjs.9582","article-title":"Consensus guidelines for enhanced recovery after gastrectomy: enhanced recovery after Surgery (ERAS(R)) society recommendations","volume":"101","author":"Mortensen","year":"2014","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.112097_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10120-016-0646-9","article-title":"Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA\/IB gastric cancer: JCOG0912","volume":"20","author":"Katai","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejso.2026.112097_bib37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/jamaoncol.2018.6727","article-title":"Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial","volume":"5","author":"Kim","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib38","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1200\/JCO.20.01210","article-title":"Long-term outcomes of laparoscopic distal gastrectomy for locally advanced GC: the KLASS-02 randomized clinical trial","volume":"38","author":"Hyung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib39","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1200\/JCO.2015.65.7692","article-title":"Effect of pathologic tumor response and nodal status on survival in the Medical research council adjuvant gastric infusional chemotherapy trial","volume":"34","author":"Smyth","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","volume":"36","author":"Lordick","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.112097_bib41","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s10120-022-01329-2","article-title":"Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial","volume":"25","author":"de Jongh","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejso.2026.112097_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.106112","article-title":"Validating a nodal regression system for gastric cancer: an ancillary cohort study of the GASTRODOC trial","volume":"94","author":"Saragoni","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejso.2026.112097_bib43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF02573066","article-title":"Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment","volume":"9","author":"Hundahl","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.soc.2011.09.005","article-title":"Surgery for gastric cancer: what the trials indicate","volume":"21","author":"Hundahl","year":"2012","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ejso.2026.112097_bib45","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.ejso.2019.06.001","article-title":"Blast from the past: perioperative use of the Maruyama computer program for prediction of lymph node involvement in the surgical treatment of gastric cancer following neoadjuvant chemotherapy","volume":"45","author":"Rawicz-Pruszynski","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112097_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106066","article-title":"Neoadjuvant immune checkpoint inhibitors for localized dMMR\/MSI-H gastric cancer: a meta-analysis","volume":"11","author":"Schwengber","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejso.2026.112097_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102890","article-title":"How do I treat dMMR\/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force","volume":"134","author":"de la Fouchardi\u00e8re","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2026.112097_bib48","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112097_bib49","doi-asserted-by":"crossref","first-page":"19427","DOI":"10.18632\/oncotarget.24827","article-title":"Distinct molecular subtypes of gastric cancer: from Laur\u00e9n to molecular pathology","volume":"9","author":"Cis\u0142o","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejso.2026.112097_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.suronc.2020.04.004","article-title":"From biology to surgery: one step beyond histology for tailored surgical treatments of GC","volume":"34","author":"Fiorillo","year":"2020","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.hoc.2024.01.003","article-title":"Advances in GC surgical management","volume":"38","author":"Stroobant","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejso.2026.112097_bib52","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/gutjnl-2013-304531","article-title":"Improved survival of GC with tumour Epstein-Barr virus positivity: an international pooled analysis","volume":"63","author":"Camargo","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.ejso.2026.112097_bib53","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3390\/cancers18122017","article-title":"Neoadjuvant immunotherapy-based treatment versus chemotherapy alone in resectable locally advanced dMMR\/MSI-H gastric cancer: a real-world study with meta-analysis","volume":"18","author":"Pang","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejso.2026.112097_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285758","article-title":"Staging LaParoscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer (POLA)\u2014Study protocol for a single-arm prospective observational multicenter study","volume":"18","author":"Rawicz-Pruszy\u0144ski","year":"2023","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.ejso.2026.112097_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000048746","article-title":"Impact of lymph node dissection on survival outcomes in GC patients receiving immune checkpoint inhibitors","volume":"105","author":"Zhang","year":"2026","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejso.2026.112097_bib56","unstructured":"ClinicalTrials.gov. Standard versus super-extended lymphadenectomy after neo-adjuvant chemotherapy for GC (Neo-D2plus). ClinicalTrials gov identifier NCT03961373."},{"key":"10.1016\/j.ejso.2026.112097_bib57","unstructured":"ClinicalTrials.gov. Phase III randomized trial comparing D2 versus D3 lymphadenectomy with GC following neoadjuvant chemotherapy (ELANCE). ClinicalTrials.gov identifier: NCT02139605."},{"key":"10.1016\/j.ejso.2026.112097_bib58","unstructured":"ClinicalTrials.gov. Lymph node 14v dissection in clinical stage T3N+, T4N+ GC (14VIGTORY). ClinicalTrials.gov identifier: NCT03264807."},{"key":"10.1016\/j.ejso.2026.112097_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.112097_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)00974-8","article-title":"Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study","author":"Shen","year":"2026","journal-title":"Lancet"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832600716X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832600716X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:44:01Z","timestamp":1793364241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832600716X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S074879832600716X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112097","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is uniform D2 still biologically optimal in gastric cancer? Lymphadenectomy in the immunotherapy era","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112097"}}